Blog Immunotherapy 360: Toxicities

Toxicities

The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.

If you have an idea for a future article, please reach out to us on our contact page!

Featured image for “A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy”

A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy

August 24, 2025
Introduction Tumor-infiltrating lymphocyte (TIL) therapy, such as lifileucel, is approved for use in adults with unresectable, advanced melanoma that has…
Featured image for “Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable”

Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable

April 23, 2025
Introduction In recent years, several antibody-drug conjugates have received approval for the treatment of gynecological cancers, adding powerful tools to…

Recent Posts

Featured image for “Anti-TIGIT Immunotherapy in Melanoma”
Sep. 01, 2025

Anti-TIGIT Immunotherapy in Melanoma

Featured image for “A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy”
Aug. 24, 2025

A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy

Featured image for “Observations Learned from Steroid Use to Manage Immune-Related Adverse Events (irAEs)”
Aug. 06, 2025

Observations Learned from Steroid Use to Manage Immune-Related Adverse Events (irAEs)

Post Categories